Abstract
N 6 -Methyladenosine (m 6 A) represents the most prevalent internal modification in mammalian mRNAs. Despite its functional importance in various fundamental bioprocesses, the studies of m 6 A in cancer have been limited. Here we show that FTO, as an m 6 A demethylase, plays a critical oncogenic role in acute myeloid leukemia (AML). FTO is highly expressed in AMLs with t(11q23)/MLL rearrangements, t(15;17)/PML-RARA, FLT3-ITD, and/or NPM1 mutations. FTO enhances leukemic oncogene-mediated cell transformation and leukemogenesis, and inhibits all-trans-retinoic acid (ATRA)-induced AML cell differentiation, through regulating expression of targets such as ASB2 and RARA by reducing m 6 A levels in these mRNA transcripts. Collectively, our study demonstrates the functional importance of the m 6 A methylation and the corresponding proteins in cancer, and provides profound insights into leukemogenesis and drug response.
Original language | English (US) |
---|---|
Pages (from-to) | 127-141 |
Number of pages | 15 |
Journal | Cancer Cell |
Volume | 31 |
Issue number | 1 |
DOIs | |
State | Published - Jan 9 2017 |
Externally published | Yes |
Keywords
- AML
- ASB2
- ATRA
- cell differentiation
- FTO
- leukemogenesis
- m6A
- RARA
- RNA modification
- RNA stability
ASJC Scopus subject areas
- Oncology
- Cell Biology
- Cancer Research